title: Orally delivered microencapsulated probiotic formulation favorably impacts polyp formation in APC (Min/+) model of intestinal carcinogenesis.
abstract: The development of intestinal polyps in an orthotopic colorectal mouse model, receiving a probiotic yogurt formulation containing microencapsulated live Lactobacillus acidophilus cells was investigated. The expression of various immunohistochemical markers namely CD8, Mac-1, Ki-67, and cleaved caspase-3, was evaluated. Results suggest that the probiotic formulation decreases overall intestinal inflammation. Mice receiving the probiotic formulation were found to develop almost two-fold fewer tumors in the small intestines. In the large intestine, however, there was no significant difference observed among polyp numbers. The formulation appears to have potential application in the prevention of various GI pathological conditions.
authors: a Biomedical Technology and Cell Therapy Research Laboratory, Departments of Biomedical Engineering and Physiology Artificial cells and Organs Research Center , Faculty of Medicine, McGill University , University Street, Montreal , QC , Canada.
authors: Aleksandra Malgorzata
authors: AM
authors: Urbanska
authors: a Biomedical Technology and Cell Therapy Research Laboratory, Departments of Biomedical Engineering and Physiology Artificial cells and Organs Research Center , Faculty of Medicine, McGill University , University Street, Montreal , QC , Canada.
authors: Jasmine
authors: J
authors: Bhathena
authors: a Biomedical Technology and Cell Therapy Research Laboratory, Departments of Biomedical Engineering and Physiology Artificial cells and Organs Research Center , Faculty of Medicine, McGill University , University Street, Montreal , QC , Canada.
authors: Sofiane
authors: S
authors: Cherif
authors: a Biomedical Technology and Cell Therapy Research Laboratory, Departments of Biomedical Engineering and Physiology Artificial cells and Organs Research Center , Faculty of Medicine, McGill University , University Street, Montreal , QC , Canada.
authors: Satya
authors: S
authors: Prakash
mesh_terms: D011125:Adenomatous Polyposis Coli / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D025601:Adenomatous Polyposis Coli Protein / Q000235:genetics* / Q000378:metabolism; D000284:Administration, Oral; D000464:Alginates / Q000737:chemistry; D000818:Animals; D016827:CD8 Antigens / Q000235:genetics / Q000378:metabolism; D002214:Capsules / Q000008:administration & dosage / Q000737:chemistry; D063646:Carcinogenesis / Q000187:drug effects / Q000235:genetics / Q000473:pathology; D053148:Caspase 3 / Q000235:genetics / Q000378:metabolism; D018914:Cells, Immobilized / Q000502:physiology; D004195:Disease Models, Animal; D015870:Gene Expression; D020723:Glucuronic Acid / Q000737:chemistry; D006603:Hexuronic Acids / Q000737:chemistry; D007420:Intestine, Large / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D007421:Intestine, Small / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D019394:Ki-67 Antigen / Q000235:genetics / Q000378:metabolism; D007779:Lactobacillus acidophilus / Q000502:physiology*; D016177:Macrophage-1 Antigen / Q000235:genetics / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D019936:Probiotics / Q000627:therapeutic use*
chemical_list: D025601:Adenomatous Polyposis Coli Protein; D000464:Alginates; D016827:CD8 Antigens; D002214:Capsules; D006603:Hexuronic Acids; D019394:Ki-67 Antigen; D016177:Macrophage-1 Antigen; C498355:Mki67 protein, mouse; D020723:Glucuronic Acid; C505409:Casp3 protein, mouse; D053148:Caspase 3
keywords: GI health; artificial cell; inflammatory cytokines; intestinal polyps; microencapsulation; probiotics